| Similar Articles |
|---|
 |
The Motley Fool
November 22, 2006
Steven Mallas |
Dueling Fools: Johnson & Johnson Bull Rebuttal Plenty of opportunities lie ahead for Johnson & Johnson, and even in down times, you've got a good defensive stock.   |
The Motley Fool
November 22, 2006
Brian Lawler |
Dueling Fools: Johnson & Johnson Bear Rebuttal The bottom line is that investors are putting their faith in the ability of J&J's management to acquire its way to renewing top-line growth in the coming years. |
The Motley Fool
October 12, 2007
Ryan Fuhrmann |
Dueling Fools: Johnson & Johnson Bull The bullish opinion on J&J is that the company is handling current difficulties well, and the low stock price makes for a bargain for investors. |
The Motley Fool
November 22, 2006
Steven Mallas |
Dueling Fools: Johnson & Johnson Bull There are many ways to expose one's portfolio to the health-care industry. But J&J offers the best upside potential at relatively little risk. |
The Motley Fool
July 28, 2011
Melly Alazraki |
J&J or Novartis? Novartis' businesses are an investor's delight; J&J's improving but isn't there yet. |
The Motley Fool
November 26, 2007
Brian Orelli |
Johnson & Johnson Reorganizes -- Who Wins? Johnson & Johnson announces the second phase of its reorganization plan. While it may take years to see whether the measures will help J&J, some other companies could benefit far more quickly. |
The Motley Fool
October 12, 2007
Billy Fisher |
Dueling Fools: Johnson & Johnson Bear The bearish opinion on J&J is that it is an impressive company that may have its best days behind it. |
The Motley Fool
September 17, 2010
James Early |
Today's Buy Opportunity: Johnson & Johnson The case for Johnson & Johnson is very simple: Here's a company that's been around forever, that pays a 3.5% dividend, and that's spread across arguably the most necessary sector (behind water and sewage): health care. |
BusinessWeek
December 20, 2004
Amy Barrett |
J&J: Don't Stop Dealmaking Now For years, health-care giant Johnson & Johnson has held on-again, off-again acquisition talks with medical-device maker Guidant Corp. But now, patent expirations and a thin pipeline mean the giant needs more than just Guidant. |
The Motley Fool
December 31, 2007
Brian Orelli |
Best Stock for 2008: Johnson & Johnson Down on its luck for 2007, here's why Johnson & Johnson's stock will rebound in 2008. |
The Motley Fool
June 27, 2008
Ryan Fuhrmann |
Recession-Proof Stocks: Johnson & Johnson This industry titan's stock is beaten down and should recover quite nicely when headwinds stop working against it and start to shift toward its back. |
BusinessWeek
June 18, 2007
Arlene Weintraub |
Johnson & Johnson's Next Baby? J&J could use an infusion of new drugs and devices from an acquisition such as Boston Scientific. |
The Motley Fool
January 24, 2006
Stephen D. Simpson |
Shake a Leg, J&J! J&J isn't a perfect story, but investors who buy today and hold for a while will be happy they did. |
BusinessWeek
April 17, 2006
Amy Barrett |
J&J: Reinventing How It Invents Johnson & Johnson bets on a new push for product development as a cure for its ailing stock. |
The Motley Fool
January 20, 2004
Alyce Lomax |
Is J&J Pain-Free? Fourth-quarter revenues surge, but rivals are waiting in the wings. |
The Motley Fool
June 26, 2006
Stephen D. Simpson |
J&J Makes an Expensive Deal J&J announced that it has reached an agreement with Pfizer to acquire the latter's consumer health-care business for $16.6 billion in cash. Consumer health is a fine business line, but is it worth this much money? Investors, take note. |
The Motley Fool
March 24, 2011
Anand Chokkavelu |
Rising Star Buy: Johnson & Johnson It's time to buy shares of Johnson & Johnson, the "health-care mutual fund." |
The Motley Fool
October 12, 2007
Ryan Fuhrmann |
Dueling Fools: Johnson & Johnson Bull Rebuttal The bulls say that J&J's stock record speaks for itself, and that the current negative short-term news and flagging stock price have created a compelling risk/reward trade-off for investors. |
BusinessWeek
April 17, 2006
Amy Barrett |
Unclogging J&J's Pipeline Maker of coronary stents Johnson & Johnson needs to release more products and grab back its lead in the crowded market it created. |
The Motley Fool
May 2, 2011
Anupama Pattanaik |
J&J Attempts to Create Major "Synthes"-is Johnson & Johnson will acquire the medical device maker for $21.3 billion. |
The Motley Fool
January 28, 2011
Anand Chokkavelu |
10 Core Stocks: A Johnson & Johnson Update The steady reliability of J&J stock will comfort the core of your portfolio when the market gets a boo-boo. |
The Motley Fool
October 12, 2007
Billy Fisher |
Dueling Fools: Johnson & Johnson Bear Rebuttal The bears say that J&J is a good company, but will underperform looking forward. |
BusinessWeek
September 30, 2009
Arlene Weintraub |
J&J Tries to Buy Itself a Pipeline It's snapping up biotechs, spearheading innovative alliances, and reshuffling R&D. |
The Motley Fool
October 14, 2008
Brian Orelli |
Johnson & Johnson, Heal Thyself When your brother falls, you've got to pick up the pace. |
BusinessWeek
April 23, 2007
Arlene Weintraub |
Under The Weather At J&J Johnson & Johnson's three big products have seen setbacks, with little in sight to replace them. |
BusinessWeek
June 18, 2007
Arlene Weintraub |
J&J's New Baby As other divisions stumble, Johnson & Johnson's consumer products - bolstered by a $16.6 billion addition - provide a security blanket. |
The Motley Fool
January 2, 2008
Brian Orelli |
Congestion in the OTC Market J&J already has generic competition for its new drug Zyrtec. |
BusinessWeek
January 30, 2006
Robert Barker |
Guidant Or No, J&J Is A Buy To Wall Street, Johnson & Johnson has been sounding like Dumb & Dumber. |
The Motley Fool
May 20, 2011
Andrea Kalvesmaki |
Johnson & Johnson's Billion-Dollar Move Orthopedics are the name of the game for this company's future earnings. |
BusinessWeek
December 22, 2003
Robert Barker |
A Stimulant For Depressed Drug Stocks? For a bunch of can't-miss stocks, the big drugmakers sure did miss out on 2003's bull run. The dozen drug companies in the Standard & Poor's 500-stock index have returned 10% this year, vs. the index' 22%. But the market is now failing to credit the companies' strengths. |
The Motley Fool
July 17, 2007
Ryan Fuhrmann |
Diagnosing J&J's Product Diversity Health-care giant Johnson & Johnson's blues may indicate trouble ahead for competitors. Investors, take note. |
The Motley Fool
November 29, 2007
Anders Bylund |
Mano a Mano Over Johnson & Johnson A look back at the past year at Johnson & Johnson. |
The Motley Fool
August 24, 2010
Matt Koppenheffer |
How Much Is Johnson & Johnson Worth? Is Johnson & Johnson's stock on sale? |
The Motley Fool
October 17, 2007
Brian Orelli |
J&J Puts Band-Aid on the Quarter Investors, Johnson & Johnson's earnings report reads like a one-hit wonder's second album. It goes from good to bad in the blink of an eye -- or in this case, a paragraph or so. |
The Motley Fool
June 30, 2006
Stephen D. Simpson |
Johnson & Johnson: This Is More Like It Filling out the drug and device businesses will be good for growth. Investors, take note. |
The Motley Fool
September 24, 2010
Anand Chokkavelu |
10 Core Stocks for Your Portfolio: Johnson & Johnson The health care behemoth makes the list |
The Motley Fool
January 12, 2006
Stephen D. Simpson |
The Guidant Auction Continues Johnson & Johnson hopes to save the deal with a last-minute raise of its offer. Although Boston Scientific's offer is $4 per share higher, that doesn't necessarily make it the best value. Investors, take note. |
BusinessWeek
October 10, 2005 |
J&J: How A Dealmaker Nurtures Newcomers Johnson & Johnson has a good track record for retaining employees after a takeover. The company's broadly decentralized structure, which gives managers great leeway - no small thing for execs used to running their own shows. |
The Motley Fool
December 21, 2006
Ryan Fuhrmann |
Dueling Fools: Merck Bear Investors, because of its recent run-up, the risk/reward tradeoff is not very compelling. There are safer, more lucrative ways to invest in the space. |
The Motley Fool
April 13, 2006
Doug Short |
A Foolish Baby Shower: Johnson & Johnson If you're an advocate of these two rules -- "It's never too early to start investing" and "Invest in what you know" -- then here is an ideal pick for baby's first stock. |
The Motley Fool
July 16, 2008
Brian Orelli |
J&J's Lesson to Investors: Diversify! Johnson & Johnson's second-quarter earnings report gives investors an object lesson of the benefits of the principle of diversification. |
The Motley Fool
September 23, 2004
Rich Smith |
Insurers vs. Big Pharma The debate over pill-splitting has gone on for some time and will continue to have an effect on the stock prices of whichever side is winning in any given quarter, be it Big Pharma or big insurance and its generic drug allies. |
The Motley Fool
November 3, 2005
Stephen D. Simpson |
The At-Odds Couple Johnson & Johnson seems to want out, but Guidant looks willing to grab the shotgun to see that this union is completed. Investors, should the deal fall through, look for J&J to continue shopping and don't be surprised if Guidant attracts attention from Abbott Labs or Boston Scientific. |
The Motley Fool
July 26, 2005
Rich Smith |
J&J: One Pricey Stock This giant of the health-care world reported its second quarter 2005 earnings last week but, by all appearances, failed to impress Wall Street. Johnson & Johnson's become very big, very pricey. |
The Motley Fool
January 10, 2007
John Reeves |
Is Your Stock a Dog? A dividend yield can be a very misleading ratio, and when it comes to identifying stable companies that deliver regular and growing cash flows, you must look deeper than just a single metric. |
The Motley Fool
May 31, 2007
Ryan Fuhrmann |
Dueling Fools: Eli Lilly Bull Rebuttal Investors need to keep looking for further proof that Lilly's valuation premium to its peers is fully warranted, but if current trends are any indication, its growth prognosis could lead the industry. |
The Motley Fool
August 29, 2008
Richards et al. |
Fool Blog: Stocks We'd Recommend to Our Grandmas In lieu of this crazy market, analysts suggest stocks they would recommend for their own grandmothers? |
The Motley Fool
October 26, 2011 |
A Brief History of Johnson & Johnson's Returns J&J shares are much more reasonably valued today than they were ten years ago; shareholders are unlikely to experience the same going forward. |
The Motley Fool
April 13, 2004
Alyce Lomax |
J&J Makes the Day It may be over a hundred years old, but the company reports a spry first quarter. |
The Motley Fool
February 24, 2004
Alyce Lomax |
J&J, Guidant Join Forces With intense rivalry looming, is a competitive partnership in vain? |
